Hyderabad, Andhra Pradesh -- (SBWIRE) -- 07/02/2012 -- ReportReserve’s pharmaceuticals report, “Novo Nordisk A/S - Product Pipeline Review - 2012” provides data on the Novo Nordisk A/S’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Novo Nordisk A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from Novo Nordisk A/S and industry-specific third party sources, put together by Global Markets Direct’s team.
- Novo Nordisk A/S - Brief Novo Nordisk A/S overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Novo Nordisk A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Novo Nordisk A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Novo Nordisk A/S’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Novo Nordisk A/S’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Novo Nordisk A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Novo Nordisk A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Novo Nordisk A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Novo Nordisk A/S and identify potential opportunities in those areas.
For further information visit http://www.reportreserve.com/report/novo-nordisk-a-s-%E2%80%93-product-pipeline-review-%E2%80%93-2012-report-542737